Pneumococcal Vaccines: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797451
  • Drug Pipelines
  • 131 pages
  • Datamonitor Healthcare
1 of 3
Prevnar 13 will continue to dominate the lucrative pediatric segments in the US and EU markets, but could be superseded in the elderly by Merck & Co’s 15-valent conjugate vaccine.

This report addresses the following questions:

- How will sales of pneumococcal vaccines change during 2016-25?
- How will vaccination rates for pneumococcal disease change over the forecast period?
- How will recent and future updates to national vaccination recommendations impact vaccine sales?
- How will the launch of novel conjugate vaccines (V114 and GSK-3) affect the landscape of the pneumococcal vaccines market?
- Which clinical criteria must pipeline vaccines meet in order to usurp Prevnar 13?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: PNEUMOCOCCAL VACCINES

- Executive Summary
- Market Overview and Trends
- Market Definition
- US Market Forecast
- Japan Market Forecast
- France Market Forecast
- Germany Market Forecast
- Italy Market Forecast
- Spain Market Forecast
- UK Market Forecast
- Key Opinion Leader Research

MARKETED DRUGS: PNEUMOCOCCAL VACCINES

- Executive Summary
- Product Overview
- Product profile: Pneumovax
- Product profile: Prevnar
- Product profile: Synflorix

PIPELINE: PNEUMOCOCCAL VACCINES

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): GSK
- Product profile (late stage): V114
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll